Jennifer B. Green
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Cardiovascular Function and Risk Factors, Metabolism, Diabetes, and Cancer, Diabetes, Cardiovascular Risks, and Lipoproteins
Most-Cited Works
- → Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes(2015)2,564 cited
- → Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial(2018)1,728 cited
- → Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials(2022)918 cited
- → Atrial Fibrillation and Diabetes Mellitus(2019)382 cited
- → Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum(2017)365 cited
- → Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association(2022)352 cited
- → Heart Failure With Preserved Ejection Fraction and Diabetes(2019)325 cited
- → The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study(2018)236 cited
- → Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus(2016)218 cited
- → Moderated ePoster Session 2(2014)162 cited